Andere Sprachen Shionogi & Co., Ltd.

Aktien

855648

JP3347200002

4507

Markt geschlossen - Japan Exchange Andere Börsenplätze 08:00:00 26.04.2024			% 5 Tage	% 1. Jan.
7’306 ^JPY	+2.21%		+2.24%	+7.47%

18.04.	Shionogi & Co, Ltd. gibt neue Daten aus der europäischen Real-World-Evidence-Studie (PERSEUS) zu Fetroja®/F etcroja® (cefiderocol) bekannt	CI
29.03.	Shionogi schließt Aktienrückkauf im Wert von bis zu 75 Mrd. Yen ab	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Shionogi & Co., Ltd. Revises Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024	25.04.
Shionogi & Co., Ltd. - Notice regarding introduction of a Restricted Stock Compensation Plan for Vice Presidents	23.04.
Shionogi & Co., Ltd. - Notice Regarding Completion of Cancellation of Treasury Shares	19.04.
ESCMID Global 2024, Shionogi presents real-world data demonstrating efficacy of Fetcroja, Fetroja in critically ill patients with certain difficult-to-treat bacterial infections	19.04.
Shionogi & Co Completes Cancellation of 10.84 Million Treasury Shares	19.04.
Shionogi & Co., Ltd. Announces New Data from the European Real-World Evidence Study of Fetroja®/F etcroja® (cefiderocol)	18.04.
Shionogi - The European Commission Grants Orphan Medicinal Product Designation for Zatolmilast, a Potential First-In-Class Treatment Being Investigated for Fragile X Syndrome	12.04.
Shionogi Completes Up to 75 Billion Yen Share Buyback	29.03.
Tranche Update on Shionogi & Co., Ltd.'s Equity Buyback Plan announced on July 31, 2023.	28.03.
Shionogi & Co., Ltd.'s Equity Buyback announced on July 31, 2023, has closed with 10,842,100 shares, representing 3.73% for ¥74,999.22 million.	22.03.
FunPep Company Limited announced that it has received ¥199.9998 million in funding from Shionogi & Co., Ltd.	21.03.
Shionogi & Co., Ltd. - Recognized as One of the Highest-Ranking Companies on the Supplier Engagement Rating by CDP for the Fourth Consecutive Year	08.03.
GSK Unit ViiV Healthcare's Injectable HIV Treatment Shows 'Superior Efficacy' in Late-stage Trial	07.03.
Shionogi & Co., Ltd. - Notice Regarding the Status of Acquisition of Own Shares	06.03.
Shionogi Announces Xocova Obtained Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection	06.03.
Shionogi Buys Back Shares Worth Nearly 12 Billion Yen	06.03.
ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses \| GSK	05.03.
GSK says ViiV's cabotegravir study supports longer HIV dose interval	05.03.
GSK's ViiV Healthcare Says Four-month Interval Between Doses Possible for HIV Treatment Cabotegravir	05.03.
Shionogi & Co., Ltd. Announces Xocova Obtains Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection	05.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Shionogi & Co., Ltd.

Aktien

855648

JP3347200002

4507

Andere Sprachen

Filter